Keith Goldan Biography and Net Worth

Chief Financial Officer of Syndax Pharmaceuticals

Keith Goldan has served as our Chief Financial Officer since June 2022.

Keith served as Chief Financial Officer of Optinose, a publicly traded specialty pharmaceutical company, since January 2017, where he helped build the infrastructure to support the launch of its lead product in the United States. Prior to Optinose, he served as Chief Financial Officer and Senior Vice President of Fibrocell, a publicly traded cell and gene therapy company. Keith’s experience also includes Chief Financial Officer roles at NuPathe, PuriCore plc and Biosyn, as well as financial roles at ViroPharma and KPMG. In these positions, Keith led finance, accounting, IT, HR and corporate development teams and successfully raised capital through multiple IPOs, capital markets transactions and financing vehicles.

Keith received a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from the Wharton School at the University of Pennsylvania.

What is Keith A. Goldan's net worth?: The estimated net worth of Keith A. Goldan is at least $1.82 million as of July 16th, 2025. Mr. Goldan owns 92,450 shares of Syndax Pharmaceuticals stock worth more than $1,824,963 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Goldan may own. Learn More about Keith A. Goldan's net worth.
How do I contact Keith A. Goldan?: The corporate mailing address for Mr. Goldan and other Syndax Pharmaceuticals executives is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. Syndax Pharmaceuticals can also be reached via phone at (781) 419-1400 and via email at [email protected]. Learn More on Keith A. Goldan's contact information.
Has Keith A. Goldan been buying or selling shares of Syndax Pharmaceuticals?: Keith A. Goldan has not been actively trading shares of Syndax Pharmaceuticals during the last quarter. Most recently, Keith A. Goldan sold 1,296 shares of the business's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a transaction totalling $12,039.84. Following the completion of the sale, the chief financial officer now directly owns 92,450 shares of the company's stock, valued at $858,860.50. Learn More on Keith A. Goldan's trading history.
Who are Syndax Pharmaceuticals' active insiders?: Syndax Pharmaceuticals' insider roster includes Fabrice Egros (Director), Neil Gallagher (President, Head of Research and Development), Keith Goldan (Chief Financial Officer), Pierre Legault (Director), Michael Metzger (COO), William Meury (Director), Michael Meyers (SVP), Briggs Morrison (CEO), Alexander Nolte (CAO), Peter Ordentlich (Insider), and Dennis Podlesak (Director). Learn More on Syndax Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Syndax Pharmaceuticals?: In the last year, insiders at the sold shares 8 times. They sold a total of 226,220 shares worth more than $3,602,021.07. The most recent insider tranaction occured on September, 8th when CEO Michael A Metzger sold 157,307 shares worth more than $2,581,407.87. Insiders at Syndax Pharmaceuticals own 4.1% of the company. Learn More about insider trades at Syndax Pharmaceuticals.
Information on this page was last updated on 9/8/2025.

Keith A. Goldan Insider Trading History at Syndax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/16/2025	Sell	1,296	$9.29	$12,039.84	92,450
2/10/2025	Sell	3,777	$15.50	$58,543.50	90,746
6/14/2024	Buy	1,250	$20.03	$25,037.50	52,623
6/13/2023	Sell	577	$22.31	$12,872.87	2,628

Keith A. Goldan Buying and Selling Activity at Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $19.74

$19.31

$20.03

50 Day Range

MA: $16.20

$13.11

$20.12

2 Week Range

Now: $19.74

$8.58

$20.20

Volume

1,489,110 shs

Average Volume

2,328,854 shs

Market Capitalization

$1.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48